Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Viking Therapeutic (VKTX) PT Lowered to $20 at Maxim Group, Remains Bullish
March 14, 2019 7:35 AM EDTMaxim Group analyst Jason McCarthy lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $20.00 (from $28.00) while maintaining a Buy rating following Q4.
Viking reported 4Q18 with a net loss of ($5.6M) and ended the year with $302M in cash on the balance sheet. Over the course of 2018, the NASH space continued to deliver positive data, in... MoreViking Therapeutics (VKTX) Tops Q4 EPS by 3c
March 13, 2019 4:12 PM EDTViking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.07), $0.03 better than the analyst estimate of ($0.10).
"The past year has been a transformative period for Viking, and we are excited to continue this momentum in 2019," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "We were... More
